P1155 COVID19 大流行和疫苗接种对 IBD 患者的影响:一项多国横断面调查

P. Alavi Nejad, M. Mokhtare, F. Farsi, M. Arshadzadeh, S. Shetty, O. Eslami, M. Arefi, M. H. Emara, E. Abdelsameea, J. Rezaei, S. M. A. Alavi, Q. T. Tran, R. Salma, A. Parsi, M. H. Ahmed, A. Monged, A. Quadri, A. Jawad, A. U. Rehman, S. H. Lee, N. S. Behl, E. Ghoneem
{"title":"P1155 COVID19 大流行和疫苗接种对 IBD 患者的影响:一项多国横断面调查","authors":"P. Alavi Nejad, M. Mokhtare, F. Farsi, M. Arshadzadeh, S. Shetty, O. Eslami, M. Arefi, M. H. Emara, E. Abdelsameea, J. Rezaei, S. M. A. Alavi, Q. T. Tran, R. Salma, A. Parsi, M. H. Ahmed, A. Monged, A. Quadri, A. Jawad, A. U. Rehman, S. H. Lee, N. S. Behl, E. Ghoneem","doi":"10.1093/ecco-jcc/jjad212.1285","DOIUrl":null,"url":null,"abstract":"\n \n \n The aim of current study is to evaluate impact of COVID19 pandemic and vaccination against it on the course and symptoms of IBD.\n \n \n \n During a six months’ period, all of the IBD cases who attend in outpatient clinics of nine referral centers in 6 countries include and request to fill a questionnaire about their demographic characters and pattern of IBD, any history of involvement with COVID19 and their vaccination history.\n \n \n \n overall 812 cases from 16 countries included (52.4% male) with average age of 36.8 y (range 7 – 76). 68.5% of participants diagnosed as UC and 29.5% as CD. 80% of participants have vaccinated against COVID19 (average 2.3 times, range 1 – 5). Among those who vaccinated (group A) 31.6% experienced side effects and complication without any mortality. The most common complications of vaccination include fever (24%), fatigue (20.1%) and anorexia 8.6%. The most common reasons for vaccination refusal (group B) were fear of vaccine complication (55.5%), no believe in vaccine protection (29.6%) and fear of immunocompromised condition (17.9%). In group A overall 61% of participants involved with COVID 19 (36.2% after vaccination) in comparison with 48.1% in group B (P = 0.0052). Most of the involvements in both groups were not sever and just a minority of patients admitted to hospital (10% in group A and 6.4% in group B). Following COVID involvement, 45.1% of cases suffered with GI symptoms (mostly diarrhea (72.5%) and abdominal pain (64.5%)). In group A, 37.3% of involvements have happened before vaccination.\n \n \n \n Vaccination against COVID19 is safe and effective among IBD patients and following vaccination, most of complications are minor and negligible. In case of COVID involvement, it would not be serious and there is no need to hold the medications. Among IBD patients, the most common reason for vaccination refusal is fear of vaccine side effect.\n","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P1155 Impact of COVID19 pandemic and vaccination among IBD patients: a multinational cross sectional survey\",\"authors\":\"P. Alavi Nejad, M. Mokhtare, F. Farsi, M. Arshadzadeh, S. Shetty, O. Eslami, M. Arefi, M. H. Emara, E. Abdelsameea, J. Rezaei, S. M. A. Alavi, Q. T. Tran, R. Salma, A. Parsi, M. H. Ahmed, A. Monged, A. Quadri, A. Jawad, A. U. Rehman, S. H. Lee, N. S. Behl, E. Ghoneem\",\"doi\":\"10.1093/ecco-jcc/jjad212.1285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n The aim of current study is to evaluate impact of COVID19 pandemic and vaccination against it on the course and symptoms of IBD.\\n \\n \\n \\n During a six months’ period, all of the IBD cases who attend in outpatient clinics of nine referral centers in 6 countries include and request to fill a questionnaire about their demographic characters and pattern of IBD, any history of involvement with COVID19 and their vaccination history.\\n \\n \\n \\n overall 812 cases from 16 countries included (52.4% male) with average age of 36.8 y (range 7 – 76). 68.5% of participants diagnosed as UC and 29.5% as CD. 80% of participants have vaccinated against COVID19 (average 2.3 times, range 1 – 5). Among those who vaccinated (group A) 31.6% experienced side effects and complication without any mortality. The most common complications of vaccination include fever (24%), fatigue (20.1%) and anorexia 8.6%. The most common reasons for vaccination refusal (group B) were fear of vaccine complication (55.5%), no believe in vaccine protection (29.6%) and fear of immunocompromised condition (17.9%). In group A overall 61% of participants involved with COVID 19 (36.2% after vaccination) in comparison with 48.1% in group B (P = 0.0052). Most of the involvements in both groups were not sever and just a minority of patients admitted to hospital (10% in group A and 6.4% in group B). Following COVID involvement, 45.1% of cases suffered with GI symptoms (mostly diarrhea (72.5%) and abdominal pain (64.5%)). In group A, 37.3% of involvements have happened before vaccination.\\n \\n \\n \\n Vaccination against COVID19 is safe and effective among IBD patients and following vaccination, most of complications are minor and negligible. In case of COVID involvement, it would not be serious and there is no need to hold the medications. Among IBD patients, the most common reason for vaccination refusal is fear of vaccine side effect.\\n\",\"PeriodicalId\":15453,\"journal\":{\"name\":\"Journal of Crohn's and Colitis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Crohn's and Colitis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/ecco-jcc/jjad212.1285\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Crohn's and Colitis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ecco-jcc/jjad212.1285","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在评估 COVID19 大流行和接种疫苗对 IBD 病程和症状的影响。 在为期 6 个月的时间里,6 个国家的 9 个转诊中心门诊部收治了所有 IBD 病例,并要求他们填写一份调查问卷,内容涉及其人口统计学特征、IBD 发病模式、COVID19 疫苗接种史以及疫苗接种史。68.5%的参与者被诊断为 UC,29.5%被诊断为 CD。80%的参与者接种过COVID19疫苗(平均2.3次,1-5次不等)。在接种过疫苗的人(A 组)中,31.6% 出现过副作用和并发症,但无死亡病例。最常见的疫苗接种并发症包括发烧(24%)、疲劳(20.1%)和厌食(8.6%)。拒绝接种疫苗(B 组)的最常见原因是担心疫苗并发症(55.5%)、不相信疫苗的保护作用(29.6%)和担心免疫力低下(17.9%)。在 A 组中,61% 的参与者参与了 COVID 19(接种后为 36.2%),而 B 组为 48.1%(P = 0.0052)。两组中大多数患者的病情并不严重,只有少数患者入院治疗(A 组为 10%,B 组为 6.4%)。COVID受累后,45.1%的病例出现消化道症状(主要是腹泻(72.5%)和腹痛(64.5%))。在 A 组中,37.3%的病例是在接种疫苗前发病的。 在 IBD 患者中接种 COVID19 疫苗是安全有效的,接种后出现的大多数并发症都很轻微,可以忽略不计。如果感染 COVID,情况不会很严重,也无需保留药物。在 IBD 患者中,拒绝接种疫苗的最常见原因是害怕疫苗的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
P1155 Impact of COVID19 pandemic and vaccination among IBD patients: a multinational cross sectional survey
The aim of current study is to evaluate impact of COVID19 pandemic and vaccination against it on the course and symptoms of IBD. During a six months’ period, all of the IBD cases who attend in outpatient clinics of nine referral centers in 6 countries include and request to fill a questionnaire about their demographic characters and pattern of IBD, any history of involvement with COVID19 and their vaccination history. overall 812 cases from 16 countries included (52.4% male) with average age of 36.8 y (range 7 – 76). 68.5% of participants diagnosed as UC and 29.5% as CD. 80% of participants have vaccinated against COVID19 (average 2.3 times, range 1 – 5). Among those who vaccinated (group A) 31.6% experienced side effects and complication without any mortality. The most common complications of vaccination include fever (24%), fatigue (20.1%) and anorexia 8.6%. The most common reasons for vaccination refusal (group B) were fear of vaccine complication (55.5%), no believe in vaccine protection (29.6%) and fear of immunocompromised condition (17.9%). In group A overall 61% of participants involved with COVID 19 (36.2% after vaccination) in comparison with 48.1% in group B (P = 0.0052). Most of the involvements in both groups were not sever and just a minority of patients admitted to hospital (10% in group A and 6.4% in group B). Following COVID involvement, 45.1% of cases suffered with GI symptoms (mostly diarrhea (72.5%) and abdominal pain (64.5%)). In group A, 37.3% of involvements have happened before vaccination. Vaccination against COVID19 is safe and effective among IBD patients and following vaccination, most of complications are minor and negligible. In case of COVID involvement, it would not be serious and there is no need to hold the medications. Among IBD patients, the most common reason for vaccination refusal is fear of vaccine side effect.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Prolonged time to diagnosis of Crohn’s disease in patients with perianal fistulas negatively affects long-term outcomes Oxidized polyunsaturated fatty acid promotes colitis and colitis-associated tumorigenesis in mice Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease IL23R-specific CAR Tregs for the treatment of Crohn’s disease Colorectal cancer in inflammatory bowel disease: a review of the role of gut microbiota and bacterial biofilms in disease pathogenesis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1